Indian Pharmaceutical Companies Race to Market Affordable Weight-Loss Drugs

Indian pharmaceutical companies are rapidly launching lower-cost versions of popular weight-loss drugs, driven by increasing demand for affordable obesity and diabetes treatments in the world’s most populous nation. This surge in competition is likewise prompting increased regulatory scrutiny.

Sun Pharmaceutical Leads the Charge

Sun Pharmaceutical Industries, founded by billionaire Dilip Shanghvi, recently introduced semaglutide pen injections under the brand names Noveltreat and Sematrinity [Forbes]. Noveltreat is priced at approximately INR3,600 (US$38.30) per month for the lowest dose, while Sematrinity costs INR3,000 per month – significantly less than the cost of Ozempic and Wegovy [VNExpress]. Kirti Ganorkar, managing director of Sun Pharmaceutical, stated the company’s aim is to “provide a high-quality, affordable therapy to a wider patient community in India.”

Other Indian Billionaires Enter the Market

Sun Pharmaceutical is not alone in this endeavor. Dr. Reddy’s Laboratories, owned by billionaires Satish Reddy and G. V. Prasad, has launched Obeda, an injection for managing type 2 diabetes, priced at INR4,200 per month [VNExpress]. Alongside Obeda, Dr. Reddy’s plans to develop an integrated care ecosystem, including metabolic centers focused on improving treatment for diabetes and related metabolic conditions. CEO Erez Israeli emphasized the company’s vision of ensuring “advanced diabetes treatments are not only available but affordable.”

Torrent Pharmaceuticals, controlled by billionaire brothers Sudhir Mehta and Samir Mehta, has also launched both injectable and oral weight-loss drug versions under the brands Sembolic and Semalix, priced at INR3,999 per month [VNExpress]. CEO Amal Kelshikar highlighted Torrent’s commitment to expanding treatment options for complex metabolic conditions at affordable prices.

GLP-1 and the Growing Need for Obesity Treatment

These drugs work by utilizing GLP-1, a hormone that regulates blood sugar levels and reduces appetite, aiding in weight control and the management of type 2 diabetes.

India’s Role and Market Potential

With over 100 million people in India living with diabetes [VNExpress] and approximately 8% of the population considered obese according to the World Health Organization, the demand for affordable weight-loss solutions is substantial. India is increasingly recognized as a key low-cost supplier in the global fight against obesity, mirroring its past success in driving down the cost of HIV treatments.

Analysts predict a potential market expansion to $1 billion [VNExpress], with a possible price war that could reduce the cost of some weight-loss drugs in India by up to 90%, potentially impacting other markets.

Regulatory Concerns and Potential Risks

The rapid influx of generic weight-loss drugs has prompted increased oversight from India’s Ministry of Health. The ministry has expressed concerns about the on-demand availability of these drugs through various channels and the potential for serious adverse effects if used without proper medical supervision [VNExpress]. Restrictions have been imposed on marketing practices to prevent misleading consumers and encourage off-label usage.

Some doctors have cautioned against viewing these drugs as “magic pills,” warning of potential dependence and the importance of combining medication with proper diet and lifestyle changes. Mumbai-based diabetologist Rahul Baxi reportedly refused to prescribe weight-loss drugs to a young man concerned about a modest weight gain, emphasizing that the drugs are not a substitute for healthy habits.